AGH Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$524K Buy
1,055
+9
+0.9% +$3.99K 0.33% 61
2026
Q1
$467K Buy
1,046
+40
+4% +$18.7K 0.34% 62
2025
Q4
$456K Buy
1,006
+71
+8% +$30.6K 0.34% 56
2025
Q3
$366K Buy
935
+399
+74% +$167K 0.27% 74
2025
Q2
$239K Sell
536
-4
-0.7% -$1.84K 0.2% 103
2025
Q1
$262K Buy
+540
New +$252K 0.25% 93

Other funds holding VRTX

AGH Wealth Advisors's VRTX Position: Q2 2026 in Review

AGH Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.86% in Q2 2026, buying an estimated $3.99K and bringing the position to 1,055 shares worth $524K. The position accounts for 0.33% of the portfolio, ranked #61.

AGH Wealth Advisors first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • AGH Wealth Advisors held 1,055 shares of Vertex Pharmaceuticals worth $524K as of Q2 2026.
  • AGH Wealth Advisors bought 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.33% of AGH Wealth Advisors's portfolio in Q2 2026, its #61 holding.
  • AGH Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on AGH Wealth Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.